Susquehanna International Group
FHTX icon

Susquehanna International Group’s Foghorn Therapeutics FHTX Stock Holding History

Susquehanna International Group’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,400
Closed -$189K – 13198
2022
Q1 		$189K Sell
12,400
-28,300
-70% -$388K ﹤0.01% 11301
2021
Q4 		$931K Buy
+40,700
New +$585K ﹤0.01% 7491

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Susquehanna International Group's FHTX Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Foghorn Therapeutics (FHTX) in Q1 2026: 11,637 shares worth $55.6K. The stake represents ﹤0.01% of the portfolio and ranks #12608 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in FHTX as recently as Q2 2025.

Susquehanna International Group first reported a position in FHTX in Q4 2020 and has held it in 11 quarters since. The position peaked at $566K in Q4 2020. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Susquehanna International Group held 11,637 shares of Foghorn Therapeutics worth $55.6K as of Q1 2026.
  • Foghorn Therapeutics was a new Susquehanna International Group position in Q1 2026.
  • Foghorn Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12608 holding.
  • Susquehanna International Group first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 11 quarters since.
  • Susquehanna International Group's Foghorn Therapeutics position peaked at $566K in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.